TriSalus Life Sciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $45.2M+53.4% YoYTTM through 31 Dec 2025
Net Income -$39.2MTTM through 31 Dec 2025
Free Cash Flow -$18.9MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 84.6% |
| Operating Margin | -59.7% |
| Net Margin | -86.9% |
Returns
N/A (negative equity)ROE
-111.0%ROA
Balance Sheet Health
Debt / EquityN/A (negative equity)
Current Ratio2.80x
Net Debt$12.6M
Cash & Equivalents$20.4M
Quality Metrics
FCF Margin-41.9%
Rule of 40-25.9
Earnings-Beat Rate33.3%
Dividend
No dividend
Segment Performance
Figures as of 31 Dec 2025
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| TriNav System | $45.2M | +53.4% | View detailsRevenues are expected to continue growing, driven by further market share increases, the commercial launch of TriNav LV, and target market expansion. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.